XM does not provide services to residents of the United States of America.

Apollo-owned Novolex to take packaging products maker Pactiv private in $6.7 bln deal



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Apollo-owned Novolex to take packaging products maker Pactiv private in $6.7 bln deal</title></head><body>

Adds details and background in paragraphs 5-10

Dec 9 (Reuters) -Packaging firm Novolex will buy rival Pactiv Evergreen PTVE.O in a $6.7 billion deal, as the Apollo Global Management-owned APO.N firm looks to bolster its business of food and beverage packaging in a cautious economic environment.

Novolex will offer $18 per share to take Pactiv private in an all-cash transaction, including debt, the companies said on Monday.

The deal represents a 32.4% premium to Pactiv's closing price on Dec. 2, a day before Bloomberg News first reported that Novolex was considering purchasing the company.

Shares of Pactiv, which sells its products to restaurants, retailers, food and beverage producers, packers and processors, jumped about 19%.

Packaging firms have been scouting for deals as easing demand following a boom fueled by e-commerce during the pandemic sparked consolidation in the sector.

Last month, Switzerland-based Amcor 485.F, AMCR.N agreed to buy U.S. peer Berry Global BERY.N for $8.4 billion. International Paper IP.N said in April it would buy British paper and packaging firm DS Smith SMDS.L.

Lower sales volumes in the food and beverage merchandising segment even led to a decline in Pactiv's third-quarter revenue last month. The company also reported a loss during the period, hurt by a rise in raw material costs.

The Novolex-Pactiv deal, supported by funds managed by affiliates of Apollo and Canada Pension Plan Investment Board, would allow the merged company to deliver 250 brands, along with expanded distribution, across the U.S., Canada and Mexico.

The combined firm will be led by Novolex Chairman and CEO Stan Bikulege.

Barclays Bank, Morgan Stanley and RBC Capital Markets are the financial advisers to Novolex, while Goldman Sachs and Lazard Freres are advisers to Pactiv.



Reporting by Anuja Bharat Mistry in Bengaluru; Editing by Shilpi Majumdar

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.